PCI Pharma Services Secures New Investment to Accelerate Global CDMO Growth

• PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, with further support from Mubadala and Partners Group.

• The funding will support PCI’s continued expansion in CDMO services, particularly in sterile fill-finish, high potency manufacturing, and geographic growth.

PCI Pharma Services, a global contract development and manufacturing organisation (CDMO), has announced a new strategic investment to accelerate its growth and service expansion. The investment is co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala Investment Company. Partners Group will also retain a minority stake in the company. Financial terms were not disclosed.

Headquartered in Philadelphia, PCI provides integrated drug development, manufacturing, and packaging services. The company has supported over 450 product launches in the past five years and has more than 50 years of experience in pharmaceutical services. The latest investment will help PCI enhance its capabilities in high potent manufacturing, sterile fill-finish of injectables, and expand its global presence.

The partnership will see Bain Capital join forces with Kohlberg, Mubadala, and PCI’s management team to support both organic and inorganic growth initiatives. These include expanding service offerings and investing further in the United States to strengthen pharmaceutical manufacturing and supply chain infrastructure.

CEO Salim Haffar said: “PCI has embarked on a purposeful journey to transform itself into a global CDMO by executing its successful growth strategy, providing industry-leading customer experience, and offering innovative and integrated supply chain solutions.”

Jefferies LLC acted as lead financial advisor to PCI, while Paul, Weiss, Rifkind, Wharton & Garrison LLP served as counsel. Bain Capital was advised by Morgan Stanley and Kirkland & Ellis LLP.